EP3153157A1 — Pharmaceutical composition for prolonged release of nevirapine
Assigned to Teva Pharmaceutical Works PLC · Expires 2017-04-12 · 9y expired
What this patent protects
The present invention relates to a pharmaceutical composition for prolonged release of nevirapine, comprising nevirapine or a pharmaceutically acceptable salt thereof as the sole pharmaceutically active ingredient and polyethylene oxide as a matrix-forming component, wherein the …
USPTO Abstract
The present invention relates to a pharmaceutical composition for prolonged release of nevirapine, comprising nevirapine or a pharmaceutically acceptable salt thereof as the sole pharmaceutically active ingredient and polyethylene oxide as a matrix-forming component, wherein the amount of the polyethylene oxide with at least 20 wt.-%, based on the total weight of the pharmaceutical composition.
Drugs covered by this patent
- Viramune (NEVIRAPINE) · Boehringer Ingelheim
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.